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A B S T R A C T
Objective. Acute kidney injury (AKI) is a common complication resulting from cardiopulmonary bypass in infants.
Urinary neutrophil gelatinase-associated lipocalin (NGAL) is a sensitive and specific marker of such injury. In this
study, we compared the performance of serum cystatin C (Cys C) and serum creatinine (Cr) as early markers of renal
dysfunction in infants undergoing cardiac surgery under bypass.
Study Design, Setting, and Patients. The study was designed as a prospective observational study. The study was
conducted in the cardiac intensive care unit (ICU) of a tertiary, academic children’s hospital in the United States.
Infants (age <1 year) undergoing cardiac surgery under cardiopulmonary bypass were included in the study.
Outcome Measure. Acute kidney injury was defined based on postoperative urinary NGAL.
Results. A total of 17 infants were included in the study, and five of them developed AKI. Serum Cys C and Cr levels
were measured postoperatively on days 1, 2, and 3, and compared with baseline levels. On postoperative day 2,
infants with AKI showed significant change from baseline in serum Cys C levels compared with non-AKI infants
(28% vs. −9%, P = .03). The two groups did not show significant differences with respect to rise in serum Cr on any
of the 3 postoperative days. Serum Cr on days 1 and 2 showed nonspecific increases in both AKI and non-AKI
groups. The area under the receiver operating characteristic curve for day 2 Cys C was 0.87 (95% CI 0.67–1.00) in
recognizing NGAL-positive AKI.
Conclusions. Postoperative serum Cys C appears to be a more specific and sensitive biomarker for NGAL-positive
AKI resulting from cardiopulmonary bypass surgery in infants undergoing cardiac surgery.
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Introduction
Acute kidney injury (AKI) is a well-recognizedpotential complication following cardiopul-
monary bypass (CPB) and circulatory arrest in
children undergoing surgery for congenital heart
disease (CHD).1 It is associated with an increase in
in-hospital mortality, longer mechanical ventila-
tion times, and longer duration of inotropic
support in these children.2,3 Hence, early identifi-
cation of AKI is essential in these patients. Serum
creatinine (Cr) is the conventional biomarker that
is commonly used to identify such AKI. But Cr is
a marker of glomerular filtration rate (GFR) rather
than injury to the kidney itself. Serum concentra-
tion does not increase significantly until approxi-
mately 50% of renal function is lost.4 As a result,
Grants and funding
This study was funded by the Caruth Center for Pedi-
atric Translational Clinical Research, Children’s
Health, Dallas, TX.
E180
© 2015 Wiley Periodicals, Inc.Congenit Heart Dis. 2015;10:E180–E188
there is a time lag between initiation of AKI and
rise in serum Cr that can result in delayed identi-
fication. Also, if early rise in serum Cr does occur,
it is nonspecific and can simply reflect prerenal
state. Hence, it has various limitations in being a
good marker for renal function in AKI.
Cystatin C (Cys C) is a cationic nonglycosylated
low-molecular-weight inhibitor of cysteine pro-
teases that is produced by all nucleated cells. It was
first proposed as a marker for GFR in 1985.5,6
There is increasing evidence that serum Cys C can
be used as an early biomarker of AKI resulting
from CPB.7,8 Multiple studies have evaluated its
performance in comparison with serum Cr.7–11 A
potential limitation of these studies is that they
define AKI based on increase in serum Cr or
decrease in Cr-based GFR measurements. Recent
evidence suggests that urinary neutrophil
gelatinase-associated lipocalin (NGAL) is a more
specific and sensitive early marker of AKI in this
patient population.12,13 The purpose of this study
was to evaluate serum Cys C as an early biomarker
of renal dysfunction in patients with NGAL-
positive AKI sustained during CPB, defining AKI
based on urinary NGAL instead of serum Cr. As a
secondary objective, we also evaluated the utility
of Cr clearance measurement based on an abbre-
viated 4-hour urine collection in this setting.
Methods
This study was performed at the cardiac intensive
care unit (ICU) in Children’s Medical Center
Dallas (CMCD) over a 1-year period from July
2011 through June 2012. It was designed as a pro-
spective observational cohort study and was
approved by the local Institutional Review Board.
We compared children with and without AKI,
with respect to serum Cys C and serum Cr. AKI
was defined as post-CPB urinary NGAL > 150 ng/
mL. The study was limited to term infants under
12 months of age as this is the age group with the
highest incidence of AKI secondary to CPB. Chil-
dren undergoing cardiac surgery under CPB
support were enrolled in the study after obtaining
informed consent and Health Insurance Portabil-
ity and Accountability Act of 1996 authorization.
Those with exposure to nephrotoxic medications
and intravenous contrast and/or evidence of AKI
prior to CPB, defined as meeting “Risk,” “Injury,”
or “Failure,” criteria of pRIFLE during the pre-
ceding 3 days before surgery, were excluded to
avoid the confounding effect on postoperative
serum Cys C level, serum Cr, and Cr clearance.14
In addition, children with evidence of chronic
kidney disease (CKD), based on either the esti-
mated Cr clearance using Schwartz’s formula or
measured Cr clearance in a 24-hour urine collec-
tion, were excluded to avoid the confounding
effect of CKD on postoperative serum Cys C
levels, serum Cr, and Cr clearance. CKD was
defined as estimated GFR less than 2 standard
deviations below age-based mean GFR.
Patient demographic data, including age,
gender, weight, type of cardiac lesion, anthropo-
metric data, and surgical information, were
obtained. Surgical complexity was ranked accord-
ing to the Risk Adjustment for Congenital Heart
Surgery 1 (RACHS-1) scoring system.15 Intraop-
erative data obtained included duration of CPB,
cross-clamp time, and circulatory arrest time.
Postoperative hourly urine output and need for
renal replacement therapy (RRT) were monitored.
Urine and serum samples were obtained prior
to surgery to measure the baseline urinary NGAL,
serum Cr, and serum Cys C. A fresh urine sample
was obtained within 4–6 hours after coming off of
CPB to measure postoperative urinary NGAL.12
Serum and urine samples were obtained on post-
operative days (POD) 1, 2, and 3 to measure serum
Cys C, serum Cr, and 4-hour urine Cr clearance
on those days.
Urine NGAL Measurement
Two mL of the urine sample collected for NGAL
measurement was sent to the core chemistry lab at
CMCD immediately after collection. The sample
was centrifuged at 1840 g for 10 minutes and
1.5 mL of supernatant was obtained and frozen
within 1 hour of collection and stored at −70°C.
Samples were sent in batches to the Biomarker
Laboratory (Cincinnati Children’s Research
Foundation, Cincinnati, OH) for analysis. They
were analyzed by enzyme-linked immunosorbent
assay (ELISA) using NGAL Rapid ELISA Kit (Kit
037, Bioporto Diagnostics, Gentofte, Denmark)
and reported in ng/mL. The cutoff used was
150 ng/mL and AKI was diagnosed if it was
>150 ng/mL.13
Serum Cys C Measurement
One mL of blood sample collected for serum Cys
C measurement was sent to the core chemistry lab
at CMCD. Serum (0.5 mL) was obtained from this
sample and frozen within 1 hour of collection and
stored at −20°C. It was then shipped to an outside
lab (Mayo Medical Laboratories, Rochester, MN).
The sample was analyzed by latex particle-
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enhanced immunonephelometry using BN II
System (Dade Behring, Deerfield, IL, USA) and
reported in mg/L.16 Serum Cys C-based GFR was
calculated using the formula log (GFR) = 1.962 +
(1.123 × log [1/CysC]).17,18 Cr-based GFR was cal-
culated using the Schwartz formula.19,20
Statistical Analysis
The cohort of patients was grouped into AKI and
non-AKI groups based on postoperative urinary
NGALmeasurements. The two groups were com-
pared with respect to baseline characteristics.
Serum Cys C and Cr between the two groups were
comparedwith respect to change frombaseline and
estimated GFR on each of PODs 1, 2, and 3. Also,
sensitivity and specificity of Cys C and Cr in iden-
tifying NGAL-positive AKI were calculated.
Receiver operating curves were constructed and
area under the curves compared. Acute kidney
injury and non-AKI groups were also compared
with respect to hourly urine output and abbreviated
4-hour Cr clearance on PODs 1, 2, and 3. Two-
tailed Wilcoxon rank sum tests and paired t-tests
were used for continuous variables and Fisher’s
exact tests for categorical variables. All statistical
analyses were performed using R version 3.1.0.21,22
Results
A total of 20 patients were enrolled in the study.
Three of the 20 patients were excluded due to
absence of postoperative urinary NGAL data. Of
the 17 patients included in the final analysis, five
developed AKI based on postoperative urinary
NGAL > 150 ng/mL. Median age of the cohort
was 76 days (range 5, 272 days) and median weight
was 3.5 kg (range 2.5 to 8.9 kg). Median surgical
complexity ranking based on risk adjustment for
congenital heart disease (RACHS-1) was 3 (range
1, 6). There was male preponderance, with 12
males and 5 females in this cohort. Eight patients
had lesions with single ventricle physiology. The
median CPB time was 108 minutes (range 21, 163
minutes) and the median aortic cross-clamp time
was 74 minutes (range 0, 103 minutes). Only three
patients had circulatory arrest (3, 9, and 16
minutes), and two of them developed AKI.
Table 1 compares baseline characteristics
between AKI and non-AKI groups. Children in
the AKI group were younger compared with non-
AKI group (median age 5 vs. 99 days, P = .007).
They also had more complex surgeries (median
RACHS-1 ranking 4 vs. 2.5, P = .04). AKI group
had longer durations of CPB (130 vs. 84 minutes,
P = .01) and cross-clamp times (92 vs. 66 minutes,
P = .06), and required other vasopressor/inotropic
support in addition to milrinone. Baseline serum
Cr was higher and Cr-based estimated baseline
GFR lower in the AKI group compared with non-
AKI group. But baseline Cys C and Cys C-based
estimated GFR were similar in the two groups.
Baseline urinary NGAL and urine output were
within normal limits in both the groups prior to
surgery.
The lowest postoperative urinary NGAL was
263 ng/mL in the AKI group. Postoperative
changes in serum Cys C and Cr for the two groups
are shown inFigure 1.TheAKIgroupdid not show
statistically significant (at α = .05) postoperative
increase in serum Cr or decrease in Cr-based GFR
compared with baseline on any of the initial 3
PODs (Table 2). Significant postoperative increase
Table 1. Baseline Characteristics—Non-AKI vs. AKI
Non-AKI Group (n = 12)
Median (Range)
AKI Group (n = 5)
Median (Range) P Value*
Age (days) 99 (5, 272) 5 (4, 16) .007
Gender—Male:Female (Expressed as Proportion) 60:40 75:25 .60
RACHS-1 ranking 2.5 (1, 6) 4 (3, 6) .04
CPB time (minutes) 84 (21, 163) 130 (115, 157) .01
Cross-clamp time (minutes) 66 (0, 98) 92 (72, 103) .06
Baseline Cr (mg/dL) 0.4 (0.3, 0.6) 0.6 (0.4, 0.8) .02
Baseline Cr-based GFR† (mL/min/1.73 m2) 66 (38, 93) 36 (26, 57) .004
Baseline CysC (mg/L) 1.2 (0.7, 1.8) 1.2 (1.0, 1.8) .79
Baseline CysC-based GFR‡ (mL/min/1.73 m2) 68 (48, 137) 75 (47, 92) .96
Baseline NGAL (ng/mL) 13 (2, 43) 19 (8, 26) .68
Baseline hourly urine output (mL/kg/hour) 2.5 (1.2, 4.3) 3.5 (1.8, 6.6) .54
*Wilcoxon rank-sum test for continuous variables and Fisher’s exact test for categorical variables. Bold values indicate statistical significance P < .05.
†GFR estimated from serum Cr using Schwartz formula.
‡GFR estimated from serum CysC using the formula log (GFR) = 1.962 + (1.123 × log [1/CysC]).
AKI, acute kidney injury; Cr, creatinine; CPB, cardiopulmonary bypass; Cys C, Cystatin C; GFR, glomerular filtration rate; NGAL, neutrophil gelatinase-associated
lipocalin.
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in serum Cys C and decrease in Cys C-based GFR
were noted on POD 2 in the AKI group (Table 2).
Interestingly, significant postoperative elevation in
serum Cr was noted in the non-AKI group. Serum
Cys C did not show such elevation in this group.
TheAKI and non-AKI groups differedwith respect
to serumCysC on PODs 2 (P = .03) and 3 (P = .09),
but not with respect to serum Cr (P = .75 and .71,
respectively) (Figure 2).
Figure 3 shows comparison between non-AKI
and AKI groups with respect to urine output and
4-hour abbreviated Cr clearance. Urine output
was a good marker of AKI on POD 1, with all
patients in the non-AKI group having a urine
output >1 mL/kg/hour and most patients in the
AKI group <1 mL/kg/hour (P = .002). But urine
output normalizes in the AKI group on PODs 2
and 3 (P = .44 and .72, respectively). Similarly,
abbreviated Cr clearance based on a 4-hour urine
collection showed significant difference between
the two groups on POD 1 (P = .002) and no
difference on days 2 and 3 (P = .64 and .54,
respectively).
Performances of Cys C-based and Cr-based
estimations of GFR to diagnose AKI were assessed
using urinary NGAL as the gold-standard test.
Decrease in GFR of ≥25% from baseline was used
as the cutoff for both Cr-based estimates and Cys
C-based estimates. Cys C showed good specificity
on each of the three PODs (0.78, 0.89, and 0.89,
respectively). But the sensitivity was poor (0.20,
0.40, and 0.50, respectively). In contrast, Cr
showed poor specificity (0.58, 0.50, and 0.75,
respectively) but better sensitivity (0.80, 0.60, and
0.40, respectively) on each of the three PODs.
When the highest decrease in GFR between days
2 and 3 was used, Cys C performed better com-
pared with Cr with respect to both sensitivity (0.80
vs. 0.60) as well as specificity (0.89 vs. 0.50). Posi-
tive predictive value was 0.80 for Cys C compared
Figure 1. The plot to the left shows percentage change from baseline in Cys C levels on days 1, 2, and 3 for AKI and
non-AKI groups. The plot on the right shows percentage change from baseline in Cr levels on days 1, 2, and 3 for AKI and
non-AKI groups. The plotted points represent mean values and the error bars show standard error. AKI, acute kidney injury;
Cr, creatinine; Cys C, Cystatin C.
Table 2. Creatinine and Cystatin C—Postoperative
Changes from Baseline
Non-AKI Group AKI Group
Mean Difference
(P Value*)
Mean Difference
(P Value*)
Increase in Cr†
Postoperative day 1 0.15 (.04) 0.24 (.05)
Postoperative day 2 0.13 (.009) 0.28 (.15)
Postoperative day 3 0.06 (.15) 0.28 (.40)
Increase in CysC‡
Postoperative day 1 0.17 (.17) 0.10 (.47)
Postoperative day 2 0.06 (.44) 0.32 (.02)
Postoperative day 3 0.11 (.33) 0.40 (.20)
Decrease in Cr-based
GFR§, ∥
Postoperative day 1 11 (.20) 6 (.40)
Postoperative day 2 13 (.02) 5 (.50)
Postoperative day 3 5 (.37) 28 (.48)
Decrease in Cys-based
GFR§, ¶
Postoperative day 1 1 (.65) 9 (.24)
Postoperative day 2 −11 (.04) 14 (.04)
Postoperative day 3 −14 (.07) 8 (.23)
*Paired t-test.
†Cr in mg/dL.
‡CysC in mg/L.
§GFR in mL/min/1.73 m2.
∥GFR estimated from serum Cr using Schwartz formula.
¶GFR estimated from serum CysC using the formula log
(GFR) = 1.962 + (1.123 × log [1/CysC]).
AKI, acute kidney injury; Cr, creatinine; Cys C, Cystatin C; GFR, glomerular
filtration rate. Bold values indicate statistical significance P < .05.
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with 0.33 for Cr, and negative predictive value was
0.89 for Cys C compared with 0.75 for Cr.
Figure 4 shows receiver operating characteristic
curves for Cys C and Cr for PODs 1, 2, and 3. The
areas under the curve for day 2 were 0.87 and 0.58,
respectively, for Cys C and Cr. A cutoff value of
about 15% increase from baseline for Cys C on
POD 2 provided the best sensitivity and specificity
(0.80 and 0.89, respectively).
Discussion
In the recent literature, serum Cys C has shown
promise as a potential early biomarker of AKI and
measure of GFR in children sustaining AKI due to
CPB. In this study, we compared Cys C with Cr in
recognizing NGAL-positive AKI. We found that
Cys C is a more specific marker of AKI compared
with Cr. Cys C levels on POD 2 had the best
discriminatory ability with an area under the
receiver operating characteristic curve of 0.87. In
contrast, there was significant elevation of Cr in
most patients after CPB, irrespective of whether
they developed AKI or not, and poor correlation
with severity of AKI as measured by post-CPB
urinary NGAL levels.
In our cohort, we noticed a significant difference
in baseline Cr as well as Cr-based estimates of GFR
between the AKI and non-AKI groups. AKI group
had higher Cr at baseline (preoperatively) even
though there was no evidence of AKI at that time as
evidenced by normal preoperative urinary NGAL
levels. This is likely reflective of the age difference
between the two groups. Because all the children
Figure 2. The figure shows box plots comparing infants with and without AKI. Top row compares the change in serum Cr
from baseline and bottom row compares change in serum Cys C levels from baseline. First column shows changes noted
on day 1, second column shows changes noted on day 2, and third column shows changed noted on day 3. AKI, acute kidney
injury; Cr, creatinine; Cys C, Cystatin C.
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with AKIwere neonates, their serumCr levels were
higher. Serum Cys C did not show such difference
between the two groups at baseline, prior to going
on CPB. Presumably this is indicative of the fact
that Cys C is a more reliable marker of AKI, espe-
cially in the neonatal age group.
Serum Cr showed a postoperative rise in both
AKI and non-AKI groups, with a mean increase of
around 40% from baseline on day 1 and of about
30–40% on day 2 in both groups. The reason for
this nonspecific rise is unclear but may be reflec-
tive of prerenal state associated with CPB rather
than true AKI. This further supports the fact that
serum Cr has poor specificity in identifying true
AKI, especially during the early stages. Serum Cys
C, on the other hand, did not show any significant
rise postoperatively in the non-AKI group, on any
of the 3 days. But, in the AKI group, there was
significant rise on POD 2. We failed to notice a
difference in Cys C levels in the AKI group on
POD 1, despite previous studies showing a rise in
Cys C levels in AKI patients as early as 8–12 hours
postinjury. The dilutional effect of CPB could
potentially explain this observation in our cohort.
Similarly, we failed to notice a difference in Cys C
levels on POD 3. This is likely suggestive of
improvement in renal function, with a return of
the Cys C levels back toward baseline on day 3.
Of the five patients with AKI, only one had sig-
nificant renal dysfunction requiring RRT. This
patient’s severe AKI was identified by a very high
urinary NGAL post-CPB (>1500 ng/mL). Also,
Figure 3. The figure shows boxplots comparing infants with and without AKI. Top row compares the hourly urine output and
bottom row compares measured Cr clearance based on a 4-hour abbreviated urine collection. First column shows changes
noted on day 1, second column shows changes noted on day 2, and third column shows changed noted on day 3. AKI, acute
kidney injury; Cr, creatinine.
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his serum Cys C was 2.2 mg/L on POD 2 and
continued to rise to 2.7 mg/L on POD 3. Serum
Cr also showed progressive worsening from days 1
to 3 in this patient. Another patient with more
severe AKI (post-CPB NGAL > 500 ng/mL) also
showed a progressively worsening serum Cys C,
peaking at 2.5 mg/L on day 3. The other three
patients with milder AKI (post-CPB NGAL
< 500 ng/mL) had short, relatively benign courses
in the cardiac ICU.
Previous studies in the recent literature have
evaluated serum Cys C as an early marker of AKI,
as well as its severity, in children sustaining AKI
secondary to CPB.7–11 They have shown that it is a
good marker. But all of these studies are limited by
the fact that AKI was defined using either serum
Cr or Cr-based estimations of GFR. In this study,
we defined AKI based on urinary NGAL levels.
The etiology for AKI in postcardiac surgery chil-
dren can be multifactorial. Urinary NGAL levels
at 4–6 hours post-CPB have been shown to detect
AKI resulting from the CPB, with excellent sensi-
tivity and specificity.12 As we were specifically
interested in identifying AKI resulting from CPB
and no other etiologies, using urinary NGAL
instead of serum Cr helped us in making a more
rational comparison between Cys C and Cr in
identifying such injury. Another major limitation
of the previous studies is the wide age range of the
cohorts. Serum Cys C levels are higher in the
infants, especially during the neonatal period.23
But this is the age group at higher risk for devel-
oping AKI. Hence, the higher Cys C levels seen in
the AKI groups in previous studies may simply
reflect the fact that the AKI group had younger
children compared with the non-AKI group. In
our study, to overcome this limitation, we
restricted the age for inclusion to less than 1 year.
Also, we evaluated the change from baseline
instead of absolute value of Cys C, thus minimiz-
ing the effect of intersubject variability.
In our study, we also found that urine output on
POD 1 is a very sensitive and specific marker for
AKI. But on subsequent days it loses its sensitivity.
This could potentially be due to aggressive usage
of diuretics during the postoperative period in
these infants. Also, abbreviated 4-hour urine col-
lection to measure Cr collection could be a poten-
tially useful way to assess renal function in these
children.
One of the major limitations of our study is the
small sample size. But in spite of this limitation, we
were able to show significant differences between
the performances of Cys C and Cr in recognizing
NGAL-positive AKI. This sample size yielded a
power of 75% (β = .25) for the estimation of area
under the receiver operating characteristic curve
for Cys C on POD 2. Being a single-center study
is another potential limitation. But, on the other
hand, the effect of institutional bias is limited as all
the patients are from a single institution. Also, our
results are consistent with previous studies that
have shown similar advantages to using serum Cys
C rather than serum Cr.
Conclusions
In our small cohort of infants undergoing cardiac
surgery under CPB, we found that serum Cys C is
an early and specific biomarker for identification
Figure 4. The figure on the left shows receiver operating characteristic curves for serum Cr on days 1, 2, and 3 to identify
NGAL-positive AKI. The figure on the right shows receiver operating characteristic curves for serum Cys C. Areas under the
curves with 95% confidence intervals for each of them are shown in the inset boxes.
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of NGAL-positive AKI. It showed best perfor-
mance characteristics as a marker of AKI on POD
2. Serum Cr, on the other hand, is a sensitive, but
very nonspecific marker of such AKI. Future
studies should focus on looking at the utility of
Cys C in identifying non-CPB AKI in children
with critical illness.
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